|
|
(17 dazwischenliegende Versionen von einem Benutzer werden nicht angezeigt) |
Zeile 1: |
Zeile 1: |
− | {{pnc}} | + | {{gohome}} |
| + | {{ft|P}} |
| + | '''CHERRYPICKING STUDIES IS NOT SCIENCE |
| + | {{qt|Reviews on covid drug development}} |
| | | |
− | current items will be put into the subsections.
| |
| | | |
− | *[[reviews on covid drug development]] | + | *'''[[scouting ideas]]''' |
− | *[[scouting ideas]]
| + | |
| | | |
− | *[[Patients on biologicals]] | + | *'''[[PHA Biologicals]]''' |
− | *[[HMGB1, RAGE]]
| + | |
− | *[[pre-Interleukin 6]]
| + | |
− | *[[post-Interleukin 6]]
| + | |
− | *[[pre-TNFalpha]]
| + | |
− | *[[post-TNFalpha]]
| + | |
− | *[[pre-Interleukin 17]]
| + | |
− | *[[post-Interleukin 17]]
| + | |
− | *[[pre-Interleukin 1]]
| + | |
− | *[[post-Interleukin 1]]
| + | |
− | *[[Inflammasome]] ''colchicine''
| + | |
− | *[[Methotrexate]]
| + | |
− | *[[other anti-inflammatory]]
| + | |
− | *[[NK-kappaB]]
| + | |
− | *[[STAT 3]]
| + | |
− | *[[JAK Janus Kinase]]
| + | |
− | *[[Corticosteroids]]
| + | |
− | *[[Cytokine absorbers]]
| + | |
− | *[[Target Complement system]]
| + | |
− | *[[Target Extracellular traps]]
| + | |
− | *[[Target Neurophils]]
| + | |
− | *[[Target Mast cells]] and kinins
| + | |
− | *[[TGF beta]]
| + | |
− | *[[Immunosuppressants]]
| + | |
− | *[[Anticoagulant in covid19]]
| + | |
− | *[[Antioxidants]]
| + | |
− | *[[HIF-EPO-Iron]]
| + | |
− | *[[Stem cells]]
| + | |
− | *[[MDSC cells]]
| + | |
− | *[[Interferons]]
| + | |
− | *[[cAMP cGMP PDE NO]]
| + | |
− | *[[TRPV* channels]]
| + | |
− | *[[Retinoids]]
| + | |
− | *[[Protease inhibitors]]
| + | |
− | *[[Tyrosine kinase inhibitors]]
| + | |
− | *[[Antineoplastic agents, traditional]]
| + | |
− | *[[Mouthrinses]]
| + | |
− | *[[Adenosinergic signaling]]
| + | |
− | *[[Purinergic signaling]]
| + | |
− | *[[Nicotinergic signaling]]
| + | |
| | | |
| + | *'''[[PHA conventional pharmacology]]''' |
| | | |
− | *[[other single compounds]] | + | *'''[[PHA retargeted compounds]]''' |
− | *[[Retargeted single compounds]]
| + | |
− | *[[Hydroxychloroquine]]
| + | |
− | *
| + | |
− | *[[Target ACE2, Spike protein]]
| + | |
− | *[[Target TMPRSS2, Spike protein]] ''any other covid targed herein''
| + | |
− | *[[other antiviral compounds]]
| + | |
− | *[[AV Remdesivir]]
| + | |
− | *[[AV Lopinavir]]
| + | |
− | *[[AV Ivermectin]]
| + | |
− | *[[AV Arabidol]]
| + | |
− | *[[AV Favipiravir]]
| + | |
| | | |
− | *[[Antibiotics]] | + | *'''[[PHA antivirals by mechanism]]''' |
| | | |
| + | *'''[[PHA pharmacophore by screened target]]''' |
| | | |
− | *[[Vitamin D]] | + | *'''[[PHA ImmunoNutrients]] |
− | *[[Anorganic nutrients Magnesium]]
| + | |
− | *[[Anorganic nutrients Selenium]]
| + | |
− | *[[Anorganic nutrients Zinc]]
| + | |
− | *[[Anorganic nutrients Lithium]]
| + | |
− | *[[Anorganic nutrients Copper]]
| + | |
− | *[[Anorganic nutrients Bismuth]]
| + | |
− | *[[Nutrition, general]]
| + | |
− | *[[Exercise, Vibration]]
| + | |
| | | |
| + | *'''[[PHA compl altern natural]]''' |
| | | |
− | *[[Traditional Chinese Medicine]] | + | *'''[[PHA within indications compounds]]''' |
− | *[[Natural compounds]]
| + | |
| | | |
− | *[[Statins]] | + | *'''[[PHA Serum products]]''' |
− | *[[Antidiabetic compounds, any]]
| + | |
− | *[[RSP - On RAS drugs]]
| + | |
− | *[[RSP - On NSAIDs]]
| + | |
| | | |
− | *[[Reconvalescent blood products, Passive vaccine]] | + | *'''[[PHA Vaccination]]''' |
− | *[[Plasmapheresis]]
| + | |
| + | PHA related options: |
| | | |
− | *[[Immunodeviation]] e.g. by adjuvants or other vaccinations
| |
| *[[Radiation therapy]] | | *[[Radiation therapy]] |
| *[[Phototherapy]] | | *[[Phototherapy]] |
− | *[[Active vaccine]] | + | *[[Electric fields]] |
− | | + | |
| *[[Treatment other concepts]] | | *[[Treatment other concepts]] |
| | | |
| | | |
| + | A concept of curative retargeting has been found by cellular lockdown with kinase inhibitors from the oncologic pharmacopoiea. |
| + | This means, virus replication can be stalled to zero w/o need of develpoment of new substances. There is no need for world |
| + | vaccination anymore. The virus needs permissible cells, and most perimissible is phosphotyrosine on its own compnents. |
| + | Paper is (not yet in PubMed) : |
| | | |
| + | *'''[https://www.sciencedirect.com/science/article/pii/S1097276520305499?via%3Dihub Growth factor receptor signaling inhibition prevents SARS-CoV-2 replication at Mol Cell 2020/08/11]''' |
| + | credentials to [https://web.de/magazine/news/coronavirus/coronavirus-blockade-zellulaerer-kommunikation-forscher-stoppen-vermehrung-sars-cov-2-35045170 Marinus Brandl] who told us about it today. |
| + | based on e.g. |
| | | |
| + | {{ttp|p=32408336|t=2020. Proteomics of SARS-CoV-2-infected host cells reveals therapy targets |pdf=|usr=}} |
| | | |
| + | ======================================================================================= |
| | | |
| + | COVID19 is now a CURABLE disease !!! |
| | | |
− | | + | ======================================================================================= |
− | | + | |
− | | + | |
− | {{tp|p=32445955|t=2020. Letter to the Editor in response to the article "Could IL-17 represent a new therapeutic target for the treatment and/or management of COVID-19-related respiratory syndrome?"|pdf=|usr=009}}
| + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | {{tp|p=32426002|t=2020. Opciones Terapeuticas En El Manejo De Covid-19 Grave: Una Perspectiva De Reumatologia.|pdf=|usr=009}}
| + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | {{tp|p=32376108|t=2020. Archetype analysis of older adult immunization decision-making and implementation in 34 countries.|pdf=|usr=009}}
| + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | {{tp|p=32426090|t=2020. COVID-19, asthma, and biologic therapies: What we need to know.|pdf=|usr=009}}
| + | |
− | | + | |
− | {{tp|p=32514854|t=2020. Biologikatherapie nach COVID-19-Infektion : Keine Reaktivierung einer COVID-19-Infektion bei positivem Antikorperstatus SARS-CoV-2 unter Biologikatherapie.|pdf=|usr=009}}
| + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | {{tp|p=32558354|t=2020. Timing of antiviral treatment initiation is critical to reduce SARS-CoV-2 viral load.|pdf=|usr=010}}
| + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | {{tp|p=32562159|t=2020. The clinical value of two combination regimens in the Management of Patients Suffering from Covid-19 pneumonia: a single centered, retrospective, observational study.|pdf=|usr=010}}
| + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | {{tp|p=32592145|t=2020. Identification of a Potential Peptide Inhibitor of SARS-CoV-2 Targeting its Entry into the Host Cells.|pdf=|usr=010}}
| + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | {{tp|p=32562594|t=2020. Pregnant Women in Trials of COVID-19: A Critical Time to Consider Ethical Frameworks of Inclusion in Clinical Trials.|pdf=|usr=010}}
| + | |
− | | + | |
− | | + | |
− | {{tp|p=32578073|t=2020. Elderly at time of COronaVIrus disease 2019 (COVID-19): possible role of immunosenescence and malnutrition.|pdf=|usr=010}}
| + | |
− | {{tp|p=32577840|t=2020. Introduction: microbes, networks, knowledge-disease ecology and emerging infectious diseases in time of COVID-19.|pdf=|usr=010}}
| + | |
− | | + | |
− | | + | |
− | {{tp|p=32588335|t=2020. COVID-19, equipoise and observational studies: a reminder of forgotten issues.|pdf=|usr=010}}
| + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | {{tp|p=32552021|t=2020. From "Infodemics" to Health Promotion: A Novel Framework for the Role of Social Media in Public Health.|pdf=|usr=010}}
| + | |
− | | + | |
− | | + | |
− | {{tp|p=32551560|t=2020. Discovery of Aptamers Targeting Receptor-Binding Domain of the SARS-CoV-2 Spike Glycoprotein.|pdf=|usr=010}}
| + | |
− | | + | |
− | | + | |
− | {{tp|p=32561608|t=2020. Role of antimalarials in COVID-19: observational data from a cohort of rheumatic patients.|pdf=|usr=010}}
| + | |
− | {{tp|p=32574109|t=2020. Structural Basis of the SARS-CoV-2/SARS-CoV Receptor Binding and Small-Molecule Blockers as Potential Therapeutics.|pdf=|usr=010}}
| + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | {{tp|p=32567239|t=2020. Advantages of Using Lotteries to Select Participants for High-Demand Covid-19 Treatment Trials.|pdf=|usr=010}}
| + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | {{tp|p=32587103|t=2020. Extending rituximab dosing intervals in patients with MS during the COVID-19 pandemic and beyond?|pdf=|usr=010}}
| + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | {{tp|p=32565309|t=2020. Effect of combination antiviral therapy on hematological profiles in 151 adults hospitalized with severe coronavirus disease 2019.|pdf=|usr=010}}
| + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | {{tp|p=32557955|t=2020. Targeting the interleukin-17 pathway to prevent acute respiratory distress syndrome associated with SARS-CoV-2 infection.|pdf=|usr=010}}
| + | |
− | | + | |
− | {{ttp|p=32579012|t=2020. COVID-19. Immunothrombosis and the gastrointestinal tract.|pdf=|usr=010}}
| + | |
− | | + | |
− | | + | |
− | | + | |
− | {{tp|p=32593196|t=2020. The Another Side of COVID-19 in Alzheimer's Disease Patients: Drug-Drug Interactions.|pdf=|usr=010}}
| + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | {{tp|p=32583729|t=2020. Immunoinformatics study to search epitopes of spike glycoprotein from SARS-CoV-2 as potential vaccine.|pdf=|usr=010}}
| + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | {{tp|p=32568012|t=2020. Sars-cov-2 host entry and replication inhibitors from Indian ginseng: an in-silico approach.|pdf=|usr=010}}
| + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | {{tp|p=32547694|t=2020. Blocking Coronavirus 19 Infection via the SARS-CoV-2 Spike Protein: Initial Steps.|pdf=|usr=011}}
| + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | {{tp|p=32566569|t=2020. Appealing for efficient, well organized clinical trials on COVID-19.|pdf=|usr=011}}
| + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | {{tp|p=32593613|t=2020. Testing of natural products in clinical trials targeting the SARS-CoV-2 (Covid-19) Viral Spike Protein-Angiotensin Converting Enzyme-2 (ACE2) interaction.|pdf=|usr=011}}
| + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | {{tp|p=32532425|t=2020. Inclusion of pregnant women in clinical trials of COVID-19 therapies: what have we learned?|pdf=|usr=011}}
| + | |
− | {{tp|p=32557557|t=2020. Harnessing resolving-based therapeutics to treat pulmonary viral infections: What can the future offer to COVID-19?|pdf=|usr=011}}
| + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | {{tp|p=32383125|t=2020. Prophylaxie post-exposition ou traitement preventif pour le syndrome respiratoire aigu severe du coronavirus 2 (SARS-CoV-2) : protocole d'etude pour une etude randomisee controlee pragmatique.|pdf=|usr=011}}
| + | |
− | | + | |
− | {{tp|p=32385712|t=2020. Inflammation resolution: a dual-pronged approach to averting cytokine storms in COVID-19?|pdf=|usr=011}}
| + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | {{tp|p=32610153|t=2020. COVID-19 trials in Italy: A call for simplicity, top standards and global pooling.|pdf=|usr=011}}
| + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | {{tp|p=32584416|t=2020. Amelioration of COVID-19 related cytokine storm syndrome: Parallels to chimeric antigen receptor-T cell cytokine release syndrome.|pdf=|usr=011}}
| + | |
− | | + | |
− | {{tp|p=32536693|t=2020. Antiviral Therapy during the Coronavirus Disease (COVID-19) Pandemic: Is It Appropriate to Treat Patients in the Absence of Significant Evidence?|pdf=|usr=011}}
| + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | {{tp|p=32572383|t=2020. Evaluation of the Inhibitory Activities of COVID-19 of Melaleuca cajuputi Oil Using Docking Simulation.|pdf=|usr=011}}
| + | |
− | | + | |
− | {{tp|p=32548601|t=2020. Ventilation in the Dental Clinic: An Effective Measure to Control Droplets and Aerosols during the Coronavirus Pandemic and Beyond.|pdf=|usr=011}}
| + | |
− | {{tp|p=32548600|t=2020. Preventive and Control Measures for the Coronavirus Pandemic in Clinical Dentistry.|pdf=|usr=011}}
| + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | {{tp|p=32544611|t=2020. Development of child immunity in the context of COVID-19 pandemic.|pdf=|usr=011}}
| + | |
− | | + | |
− | {{tp|p=32417594|t=2020. Supplements for COVID-19: A modifiable environmental risk.|pdf=|usr=011}}
| + | |
− | | + | |
− | | + | |
− | | + | |
− | {{tp|p=32407539|t=2020. Clinical Trials for COVID-19: Can we Better Use the Short Window of Opportunity?|pdf=|usr=011}}
| + | |
− | | + | |
− | {{tp|p=32311763|t=2020. Off-Label Therapies for COVID-19-Are We All In This Together?|pdf=|usr=011}}
| + | |
− | | + | |
− | | + | |
− | {{tp|p=32388748|t=2020. Reply to Rheumatologists' perspective on coronavirus disease 19: is heparin the dark horse for COVID-19?|pdf=|usr=011}}
| + | |
− | | + | |
− | {{tp|p=32575032|t=2020. Participation of more community hospitals in randomized trials of treatments for COVID-19 is needed.|pdf=|usr=011}}
| + | |
− | | + | |
− | {{tp|p=32392494|t=2020. Sample sizes in COVID-19-related research.|pdf=|usr=011}}
| + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | {{tp|p=32513242|t=2020. Blocking mineralocorticoid receptor with spironolactone may have a wide range of therapeutic actions in severe COVID-19 disease.|pdf=|usr=011}}
| + | |
− | {{tp|p=32513225|t=2020. Neutrophil Elastase Inhibitors: A potential prophylactic treatment option for SARS-CoV-2-induced respiratory complications?|pdf=|usr=011}}
| + | |
− | {{tp|p=32487260|t=2020. Precision medicine for COVID-19: a call for better clinical trials.|pdf=|usr=011}}
| + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | {{tp|p=32550078|t=2020. Heated Air Delivery by Micro-Sauna: An Experimental Treatment Prototype Concept for Coronavirus Disease 2019.|pdf=|usr=011}}
| + | |
− | | + | |
− | {{ttp|p=32563554|t=2020. Should we unstress SARS-CoV-2 infected cells?|pdf=|usr=011}}
| + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | {{tp|p=32605149|t=2020. Bioactive Indolyl Diketopiperazines from the Marine Derived Endophytic Aspergillus versicolor DY180635.|pdf=|usr=011}}
| + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | {{tp|p=32520770|t=2020. Overview of Coronavirus Disease 2019 (COVID-19): Treatment Updates and Advances.|pdf=|usr=011}}
| + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | {{tp|p=32574379|t=2020. A sugar-coated strategy to treat a rare neurologic disease provides a blueprint for a decoy glycan therapeutic and a potential vaccine for CoViD-19: An Editorial Highlight for "Selective inhibition of anti-MAG IgM autoantibody binding to myelin by an antigen specific glycopolymer"on https://doi.org/10.1111/jnc.15021.|pdf=|usr=011}}
| + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | {{tp|p=32541129|t=2020. Intermittent high dosage oxygen treats COVID-19 infection: the Chinese studies.|pdf=|usr=011}}
| + | |
− | {{tp|p=32541128|t=2020. Hyperbaric oxygen treatment of novel coronavirus (COVID-19) respiratory failure.|pdf=|usr=011}}
| + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | {{tp|p=32544799|t=2020. Immune checkpoint inhibitors: a physiology-driven approach to the treatment of coronavirus disease 2019.|pdf=|usr=011}}
| + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | {{tp|p=32399192|t=2020. Recent advances in influenza vaccines.|pdf=|usr=011}}
| + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | {{tp|p=32540428|t=2020. Eltrombopag is a potential target for drug intervention in SARS-CoV-2 spike protein.|pdf=|usr=011}}
| + | |
− | {{tp|p=32537482|t=2020. Screening and druggability analysis of some plant metabolites against SARS-CoV-2: An integrative computational approach.|pdf=|usr=011}}
| + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | {{tp|p=32552595|t=2020. Natural compounds from Clerodendrum spp. as possible therapeutic candidates against SARS-CoV-2: An in silico investigation.|pdf=|usr=011}}
| + | |
− | | + | |
− | {{tp|p=32552462|t=2020. Identification of bioactive compounds from Glycyrrhiza glabra as possible inhibitor of SARS-CoV-2 spike glycoprotein and non-structural protein-15: a pharmacoinformatics study.|pdf=|usr=011}}
| + | |
− | | + | |
− | | + | |
− | {{tp|p=32543978|t=2020. Computational investigation on Andrographis paniculata phytochemicals to evaluate their potency against SARS-CoV-2 in comparison to known antiviral compounds in drug trials.|pdf=|usr=011}}
| + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | {{tp|p=32605306|t=2020. Saxifraga spinulosa-Derived Components Rapidly Inactivate Multiple Viruses Including SARS-CoV-2.|pdf=|usr=011}}
| + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | {{tp|p=32553502|t=2020. Ultrafast response of the French Society of Pharmacology and Therapeutics to the COVID-19 pandemic.|pdf=|usr=011}}
| + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | {{tp|p=32551855|t=2020. Effects of Gene-Eden-VIR and Novirin on SARS-CoV: Implications for COVID-19.|pdf=|usr=011}}
| + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | {{tp|p=32454982|t=2020. Amid COVID-19: the importance of developing an positive adverse drug reaction (ADR) and medical device incident (MDI) reporting culture for Global Health and public safety.|pdf=|usr=011}}
| + | |
− | | + | |
− | {{tp|p=32582350|t=2020. Herbs that might be effective for the management of COVID-19: A bioinformatics analysis on anti-tyrosine kinase property.|pdf=|usr=011}}
| + | |
− | {{tp|p=32600410|t=2020. Boning up: amino-bisphophonates as immunostimulants and endosomal disruptors of dendritic cell in SARS-CoV-2 infection.|pdf=|usr=011}}
| + | |
− | | + | |
− | | + | |
− | | + | |
− | {{tp|p=32539990|t=2020. A minimal common outcome measure set for COVID-19 clinical research.|pdf=|usr=011}}
| + | |
− | | + | |
− | | + | |
− | {{tp|p=32537610|t=2020. Inhibition of metalloproteinases in therapy for severe lung injury due to COVID-19.|pdf=|usr=011}}
| + | |
− | | + | |
− | | + | |
− | {{tp|p=32540604|t=2020. Iodine, a preventive and curative agent in the COVID-19 pandemic?|pdf=|usr=011}}
| + | |
− | | + | |
− | {{tp|p=32554324|t=2020. Noradrenergic and serotonergic drugs may have opposing effects on COVID-19 cytokine storm and associated psychological effects.|pdf=|usr=011}}
| + | |
− | | + | |
− | {{tp|p=32563970|t=2020. Deceiving SARS-CoV-2 molecular-tropism clues - A combinational contemporary strategy.|pdf=|usr=011}}
| + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | {{tp|p=32545268|t=2020. Potential of Flavonoid-Inspired Phytomedicines against COVID-19.|pdf=|usr=011}}
| + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | {{tp|p=32540682|t=2020. Psychotropics drugs with cationic amphiphilic properties may afford some protection against SARS-CoV-2: A mechanistic hypothesis.|pdf=|usr=011}}
| + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | {{tp|p=32548259|t=2020. Squalene-based multidrug nanoparticles for improved mitigation of uncontrolled inflammation in rodents.|pdf=|usr=011}}
| + | |
− | {{tp|p=32601278|t=2020. Numerical evaluation of spray position for improved nasal drug delivery.|pdf=|usr=011}}
| + | |
− | | + | |
− | {{tp|p=32576928|t=2020. DREAM-in-CDM Approach and Identification of a New Generation of Anti-inflammatory Drugs Targeting mPGES-1.|pdf=|usr=011}}
| + | |
− | | + | |
− | | + | |
− | {{tp|p=32583289|t=2020. Statistical Evaluation of Clinical Trials Under COVID-19 Pandemic.|pdf=|usr=011}}
| + | |
− | {{tp|p=32557317|t=2020. New FDA Guidance on General Clinical Trial Conduct in the Era of COVID-19.|pdf=|usr=011}}
| + | |
− | | + | |
− | {{tp|p=32563584|t=2020. Successful Treatment of Severe COVID-19 Pneumonia With Clazakizumab in a Heart Transplant Recipient: A Case Report.|pdf=|usr=011}}
| + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | {{tp|p=32595360|t=2020. Interaction of certain monoterpenoid hydrocarbons with the receptor binding domain of 2019 novel coronavirus (2019-nCoV), transmembrane serine protease 2 (TMPRSS2), cathepsin B, and cathepsin L (CatB/L) and their pharmacokinetic properties.|pdf=|usr=011}}
| + | |
− | {{tp|p=32595359|t=2020. Potentials of plant-based substance to inhabit and probable cure for the COVID-19.|pdf=|usr=011}}
| + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | | + | |
− | {{tp|p=32565126|t=2020. Targeting the SARS-CoV-2 spike glycoprotein prefusion conformation: virtual screening and molecular dynamics simulations applied to the identification of potential fusion inhibitors.|pdf=|usr=011}}
| + | |